Hua Shen Group "sky-high" can be popularized

The highest retail price of 28800 yuan of liver cancer treatment of new drugs Licatin will be widely used in the country. Hua Shen Group (000790) today, the company received a holding subsidiary of Chengdu Huasheng Biotechnology Co., Ltd. commissioned by the Shanghai Fudan University affiliated Zhongshan Hospital, led by the Licatin IV clinical trial report, Licatin in the clinical application of targeted, mainly in the liver tumor tissue, Less damage to normal tissue. Licatin combined with tace (transcatheter arterial chemoembolization) can improve the curative effect of tace and prolong the survival time of patients.　　The drug can be used as a new method of comprehensive treatment for primary hepatocellular carcinoma in the whole country.　　Given the uncertainty of the product's academic promotion, market expansion and clinical in-depth research, it is difficult for the company to accurately assess its impact on the company's performance for 2011 and beyond. As the first monoclonal antibody targeting drug for primary hepatocellular carcinoma (HCC), Licatin currently has a maximum retail price of 28800 yuan per branch. Licatin after the listing of clinical research will also be a long-term, continuous process, the company will continue to work with the domestic large hospitals in the treatment of liver cancer many hot issues on the cooperation of many directions, multicenter research. Therefore, the clinical academic promotion and market expansion of sales volume still need a longer process.